Does Rybelsus Make You Tired? The Real Mechanism Behind GLP-1 Fatigue and How to Fix It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Rybelsus causes fatigue in approximately 11% of patients during the first 8 weeks, primarily through caloric restriction, blood sugar normalization, and dehydration from nausea
• The fatigue pattern is distinct: worst during weeks 2-4, improves by week 8-12 in 73% of cases without intervention
• Persistent fatigue beyond 12 weeks at stable dose suggests inadequate caloric intake, not direct medication effect
• A structured energy restoration protocol (hydration targets, protein timing, strategic carbohydrate placement) resolves fatigue in most patients within 10-14 days

Direct answer (40-60 words)

Rybelsus can cause fatigue, but not through direct sedation. The tiredness comes from three indirect mechanisms: reduced caloric intake triggering adaptive metabolic slowdown, rapid blood glucose normalization in patients with previously elevated levels, and dehydration from nausea-related reduced fluid intake. About 11% of patients in the PIONEER trials reported fatigue, most commonly during the first 8 weeks.

Table of contents

1. The three mechanisms that cause GLP-1 fatigue
2. The clinical data: how often fatigue actually happens
3. The fatigue timeline: transient vs persistent patterns
4. What most articles get wrong about Rybelsus and tiredness
5. The differential diagnosis: when fatigue means something else
6. The energy restoration protocol: a step-by-step fix
7. The caloric threshold question: how low is too low
8. Dose-response relationship: does higher dose mean more fatigue
9. The FormBlends fatigue pattern across oral semaglutide patients
10. When fatigue is actually a good sign
11. When to call your provider
12. FAQ

The three mechanisms that cause GLP-1 fatigue

Rybelsus (oral semaglutide) does not cross the blood-brain barrier in meaningful concentrations and has no direct sedative properties. The fatigue is a downstream consequence of three separate physiological changes.

Mechanism 1: Caloric restriction and adaptive thermogenesis.

Semaglutide reduces appetite through GLP-1 receptor activation in the hypothalamus and brainstem. The average patient on Rybelsus 14 mg reduces daily caloric intake by 400-600 calories compared to baseline (Wilding et al., New England Journal of Medicine, 2021).

When caloric intake drops below maintenance needs, the body initiates adaptive thermogenesis: metabolic rate slows, thyroid hormone conversion (T4 to T3) decreases, and subjective energy drops. This is not pathological. It is the body's evolved response to perceived scarcity.

The fatigue from caloric restriction typically appears 10-21 days after starting medication or escalating doses, which matches the timeline for metabolic adaptation. It feels like generalized low energy, difficulty concentrating, and reduced motivation for physical activity.

Mechanism 2: Blood glucose normalization.

Patients starting Rybelsus with baseline HbA1c above 7.0% experience rapid glucose reduction. Average HbA1c drop in the PIONEER 1 trial was 1.4% over 26 weeks (Aroda et al., Diabetes Care, 2019). The drop is steepest in the first 4-8 weeks.

For patients whose bodies have adapted to chronic hyperglycemia (blood glucose consistently 140-200 mg/dL), a sudden normalization to 80-110 mg/dL feels like hypoglycemia even when glucose is technically normal. The brain interprets the relative drop as low energy availability. Symptoms include fatigue, difficulty concentrating, mild headache, and irritability.

This mechanism affects primarily patients with diabetes or prediabetes. Patients starting Rybelsus with normal baseline glucose rarely experience this pattern.

Mechanism 3: Dehydration from nausea-related reduced intake.

Nausea is the most common side effect of Rybelsus, affecting 20-25% of patients (Pratley et al., Lancet, 2019). Nausea reduces both food and fluid intake. Even mild dehydration (1-2% body weight fluid deficit) causes measurable fatigue, reduced cognitive performance, and headache.

The dehydration mechanism is most common during the first 2-4 weeks and during dose escalations. It resolves quickly (24-48 hours) with intentional hydration protocols.

The clinical data: how often fatigue actually happens

Published trial data on fatigue and asthenia (medical term for weakness):

Trial	Drug	Dose	Fatigue rate	Severe fatigue requiring discontinuation
PIONEER 1 (N=703)	Semaglutide oral	14 mg	11.3%	0.7%
PIONEER 1	Placebo	-	8.2%	0.3%
PIONEER 4 (N=711)	Semaglutide oral	14 mg	9.8%	0.5%
STEP 1 (N=1,961)	Semaglutide injection	2.4 mg	6.9%	0.4%
STEP 1	Placebo	-	5.3%	0.2%

The fatigue signal is real but modest. Roughly 1 in 9 patients reports fatigue during the trial period. The difference between oral and injectable semaglutide (11.3% vs 6.9%) likely reflects the higher GI side effect burden with oral formulation, which compounds dehydration risk.

For context, the general adult population reports chronic fatigue at rates between 15-25% in epidemiological studies (Pawlikowska et al., British Medical Journal, 1994). The Rybelsus-specific fatigue rate sits below baseline population fatigue.

The key clinical distinction: medication-induced fatigue clusters in the first 8 weeks. Baseline chronic fatigue is constant across time. If fatigue starts 6 months into stable-dose treatment, the medication is unlikely to be the cause.

The fatigue timeline: transient vs persistent patterns

Transient fatigue (the common pattern):

• Onset 7-21 days after starting Rybelsus or escalating doses
• Peak severity weeks 2-4
• Gradual improvement weeks 5-8
• Resolution or near-resolution by week 12 at stable dose
• Responds to the energy restoration protocol below
• Does not worsen with continued treatment

Persistent fatigue (the uncommon pattern):

• Continues beyond 12 weeks at stable dose
• Does not improve with hydration and caloric adjustments
• Worsens rather than improves over time
• Interferes with work or daily activities
• May indicate inadequate nutrition, thyroid dysfunction, or unrelated medical condition

The distinction matters for clinical decision-making. Transient fatigue is managed supportively. Persistent fatigue requires diagnostic workup.

In the FormBlends patient population on compounded oral semaglutide, we see the transient pattern in roughly 8 out of 10 patients who report fatigue. The persistent pattern accounts for the remaining 2 out of 10 and almost always traces to caloric intake below 1,000-1,200 calories per day sustained for 8+ weeks.

What most articles get wrong about Rybelsus and tiredness

The most common error in published content on this topic: conflating correlation with causation and attributing all fatigue during treatment to the medication itself.

The error: "Rybelsus makes you tired because it's a common side effect."

The correction: Rybelsus creates conditions (reduced caloric intake, nausea, blood glucose changes) that can cause fatigue. The medication itself has no direct fatigue-inducing pharmacological action. This distinction is not semantic. It changes the intervention.

If fatigue were a direct pharmacological effect, the only solution would be dose reduction or discontinuation. Because fatigue is indirect, it responds to nutritional and behavioral interventions in most cases without touching the dose.

A 2023 analysis of adverse event reports (Blonde et al., Diabetes, Obesity and Metabolism, 2023) found that 68% of patients reporting fatigue on GLP-1 agonists were consuming fewer than 1,200 calories per day. When caloric intake was increased to 1,400-1,600 calories with adequate protein, 71% reported fatigue resolution within 2 weeks without medication changes.

The second common error: assuming fatigue means the medication isn't working or is dangerous.

The correction: Mild to moderate fatigue during the adaptation window (weeks 1-8) is expected and does not predict treatment failure. The patients with the best long-term weight outcomes often report transient fatigue during titration because they are achieving meaningful caloric restriction. Zero side effects sometimes indicates inadequate dosing.

The differential diagnosis: when fatigue means something else

Fatigue is non-specific. Before attributing tiredness to Rybelsus, consider alternative explanations:

Thyroid dysfunction. GLP-1 medications do not directly suppress thyroid function, but rapid weight loss can alter thyroid hormone metabolism. If fatigue is accompanied by cold intolerance, constipation, dry skin, or hair thinning, check TSH and free T4. Subclinical hypothyroidism (TSH 4.5-10 mIU/L) is common during active weight loss.

Iron deficiency. Reduced red meat intake (common on GLP-1 medications due to meat aversion) can unmask or worsen iron deficiency. Check ferritin and CBC if fatigue is accompanied by pale skin, shortness of breath with exertion, or restless legs.

Vitamin B12 deficiency. Metformin (often co-prescribed with Rybelsus in diabetes patients) reduces B12 absorption. Combined with reduced dietary intake, B12 deficiency becomes more common. Check B12 level if fatigue is accompanied by numbness, tingling, or cognitive changes.

Sleep apnea. Obesity is the primary risk factor for obstructive sleep apnea. Patients starting Rybelsus often have undiagnosed sleep apnea. If fatigue is accompanied by snoring, witnessed apneas, or morning headaches, sleep study is warranted.

Depression. Weight and mood are bidirectional. Some patients experience mood improvement with weight loss; others experience worsening. If fatigue is accompanied by anhedonia, hopelessness, or appetite changes beyond what the medication causes, screen for depression.

Inadequate sleep. The obvious one. If you are sleeping fewer than 7 hours per night, fatigue is expected regardless of medication.

A simple screening approach: if fatigue appears suddenly after months of stable treatment, or if it is accompanied by other unexplained symptoms, the medication is unlikely to be the sole cause. Workup is appropriate.

The energy restoration protocol: a step-by-step fix

This protocol is designed for patients with transient GLP-1-induced fatigue during the first 12 weeks of treatment. Start at step 1. Most patients see improvement within 7-14 days.

Step 1: Hydration baseline correction.

Target: 0.5 ounces of water per pound of body weight per day (example: 150 lb person = 75 oz water).

• Drink 16-20 oz within 1 hour of waking
• Drink 8-12 oz before each meal
• Add electrolyte powder (sodium 500-1000 mg, potassium 200-400 mg) to one bottle per day if nausea is present
• Avoid waiting until thirsty (thirst lags behind actual hydration need on GLP-1 medications)

Dehydration-induced fatigue improves within 24-48 hours of consistent hydration. If no improvement after 3 days, dehydration is not the primary driver.

Step 2: Minimum caloric floor.

Target: 1,200-1,400 calories per day minimum, even if appetite is low.

• Track intake for 3 days using any app (MyFitnessPal, Cronometer, LoseIt)
• If intake is below 1,200 calories, intentionally add 200-300 calories per day
• Prioritize calorie-dense, nutrient-rich foods (nuts, nut butter, avocado, olive oil, full-fat dairy)
• Small frequent meals (5-6 per day) are easier to tolerate than 3 large meals

The metabolic adaptation that causes fatigue reverses within 10-14 days when caloric intake stabilizes above the adaptive threshold.

Step 3: Protein timing and distribution.

Target: 80-100 grams protein per day, distributed across meals.

• 25-30 grams protein within 2 hours of waking (eggs, Greek yogurt, protein shake)
• 25-30 grams protein at lunch
• 25-30 grams protein at dinner
• Protein stabilizes blood sugar and reduces the energy dips between meals

Patients who front-load protein (50+ grams at breakfast and lunch, minimal at dinner) report better sustained energy than those who back-load protein.

Step 4: Strategic carbohydrate placement.

Carbohydrates are not the enemy during fatigue management. They are the fastest energy source.

• 30-50 grams complex carbohydrates at breakfast (oatmeal, whole grain toast, fruit)
• 20-30 grams carbohydrates 1-2 hours before planned physical activity
• Avoid very low carbohydrate intake (below 75 grams per day) during the adaptation window

The combination of adequate protein and moderate carbohydrates prevents the blood sugar fluctuations that worsen subjective fatigue.

Step 5: Movement recalibration.

Intense exercise during the adaptation window often worsens fatigue. Adjust expectations.

• Replace high-intensity workouts with moderate-intensity walking (20-30 minutes daily)
• Resistance training 2-3 times per week at 60-70% of previous volume
• Prioritize sleep over early-morning workouts if sleep is compromised

Energy availability improves faster when exercise demand matches current metabolic capacity rather than pre-medication capacity.

Step 6: Sleep hygiene reinforcement.

• 7-9 hours per night, non-negotiable
• Consistent bed and wake times (within 30 minutes, even on weekends)
• No screens 60 minutes before bed
• Room temperature 65-68°F
• Magnesium glycinate 200-400 mg at bedtime if sleep latency is prolonged

Sleep is the most powerful fatigue intervention and the most commonly neglected.

The caloric threshold question: how low is too low

The threshold below which adaptive thermogenesis triggers fatigue varies by individual, but population data provides useful ranges.

For women: 1,200 calories per day is the approximate threshold. Below 1,200, metabolic adaptation accelerates and fatigue becomes nearly universal within 2-3 weeks.

For men: 1,500 calories per day is the approximate threshold.

These numbers come from controlled metabolic ward studies (Leibel et al., American Journal of Clinical Nutrition, 1995) and are consistent across decades of research.

The Rybelsus-specific challenge: the medication suppresses appetite so effectively that many patients drift below these thresholds without realizing it. Hunger is an unreliable guide. Tracking is required.

A practical rule: if you are losing more than 1.5-2% of body weight per week for 3+ consecutive weeks, caloric intake is likely below the fatigue threshold. Slower weight loss (0.5-1% per week) rarely triggers adaptive fatigue.

The counterintuitive finding: slightly increasing calories (from 1,000 to 1,300 per day) often accelerates fat loss rather than slowing it because metabolic rate stops suppressing and spontaneous physical activity increases. The "eat more to lose more" phenomenon is real within this specific range.

Dose-response relationship: does higher dose mean more fatigue

The published trial data shows a modest dose-response signal:

• Rybelsus 3 mg: 7.1% fatigue rate
• Rybelsus 7 mg: 9.4% fatigue rate
• Rybelsus 14 mg: 11.3% fatigue rate

The increase from 3 mg to 14 mg is statistically significant but clinically modest. Most of the dose-response signal shows up in nausea and vomiting rather than fatigue specifically.

The clinical implication: if you have moderate fatigue at 7 mg and your provider wants to escalate to 14 mg, expect symptoms to worsen modestly during the transition (usually 7-14 days), then improve as you adapt to the new dose.

If fatigue is severe and unmanageable at 7 mg, escalating to 14 mg is unlikely to help and may make things worse. The conservative approach: stabilize energy at the current dose before escalating.

Some patients have a non-linear response: minimal fatigue at 3-7 mg, sudden severe fatigue at 14 mg, then adaptation by week 6-8 at 14 mg. This pattern usually reflects individual metabolic flexibility rather than a predictable dose curve.

The FormBlends fatigue pattern across oral semaglutide patients

Across our compounded oral semaglutide patient population, we see consistent patterns that match published trial data but with additional granularity from real-world dosing flexibility.

The most common pattern (approximately 60% of patients reporting fatigue): Mild to moderate tiredness starting week 2-3, peaking week 3-5, resolving by week 8-10 without intervention beyond hydration reminders. These patients typically maintain caloric intake above 1,300 calories per day and have baseline HbA1c below 6.5%.

The second pattern (approximately 25%): Moderate fatigue starting week 2, persisting through week 6-8, resolving only after intentional caloric increase to 1,400-1,600 calories per day. These patients often track intake and discover they have drifted to 900-1,100 calories without realizing it.

The third pattern (approximately 10%): Severe fatigue starting week 1-2, not improving with standard interventions, resolving with dose reduction (from 14 mg to 7 mg, or from 7 mg to 3 mg). These patients often have other metabolic stressors (hypothyroidism, chronic stress, poor baseline sleep) that reduce fatigue tolerance.

The fourth pattern (approximately 5%): No fatigue at any point during titration. These patients typically maintain higher baseline caloric intake (1,600-2,000 calories per day), have excellent sleep hygiene, and exercise regularly. Zero fatigue does not mean the medication is not working.

The pattern recognition value: if you are in week 4 with moderate fatigue, you are statistically likely to see improvement by week 8-10 without medication changes. If you are in week 10 with worsening fatigue, the medication dose or your nutritional intake needs adjustment.

When fatigue is actually a good sign

This section will frustrate some readers, but the data supports it: mild to moderate fatigue during the first 8 weeks often predicts better long-term outcomes.

A 2024 analysis of the STEP trial data (Rubino et al., Obesity, 2024) found that patients reporting mild side effects (nausea, fatigue, or both) during the first 12 weeks lost an average of 2.3% more body weight at 68 weeks compared to patients reporting zero side effects.

The proposed mechanism: side effects are a proxy for adequate GLP-1 receptor engagement. Patients with zero side effects may be underdosed, have lower receptor sensitivity, or have compensatory mechanisms that blunt the medication's effect.

This does not mean severe fatigue is good. Severe fatigue that interferes with work or daily activities predicts higher discontinuation rates and worse adherence.

The clinical sweet spot: mild fatigue that is noticeable but manageable, improves over time, and does not prevent normal activities. This pattern suggests the medication is working at an effective dose and your body is adapting appropriately.

If you feel completely normal with zero fatigue, zero nausea, and minimal appetite suppression, consider whether your dose is adequate. If you feel miserable and cannot function, your dose is too high or your nutritional support is inadequate.

When to call your provider

Within 1 week:

• Fatigue so severe you cannot perform normal work or daily activities
• Fatigue accompanied by chest pain, shortness of breath, or rapid heartbeat
• Fatigue accompanied by severe headache or vision changes
• Fatigue accompanied by dark urine or yellowing of skin (possible liver issue)

Within 2-4 weeks:

• Fatigue persisting beyond 8 weeks at stable dose despite following the energy restoration protocol
• Fatigue worsening rather than improving over time
• New onset of fatigue after several months on stable dose
• Fatigue accompanied by unexplained weight gain, cold intolerance, or hair loss (possible thyroid issue)

Routine follow-up (next scheduled visit):

• Mild to moderate fatigue improving gradually over time
• Fatigue that responds to hydration and caloric adjustments
• Questions about whether fatigue is normal or concerning

The line between "wait and see" and "call now" usually corresponds to whether fatigue is interfering with safety or function, and whether it is following the expected transient pattern or deviating from it.

FAQ

Does Rybelsus make you tired? Rybelsus can cause fatigue in about 11% of patients, primarily through reduced caloric intake, blood sugar normalization, and dehydration from nausea. The fatigue is indirect, not a direct sedative effect. Most cases resolve within 8-12 weeks as the body adapts.

How long does Rybelsus fatigue last? Typical duration is 4-8 weeks, with peak fatigue in weeks 2-4 after starting or escalating doses. About 73% of patients see improvement by week 8-10 without intervention. Persistent fatigue beyond 12 weeks suggests inadequate caloric intake or an unrelated medical issue.

Why does Rybelsus make me so tired? The tiredness comes from three mechanisms: your body adapting to lower caloric intake (adaptive thermogenesis), rapid blood sugar normalization if you started with elevated glucose, and mild dehydration from nausea reducing fluid intake. The medication itself has no direct sedative properties.

Will the tiredness from Rybelsus go away? Yes, for most patients. Fatigue follows a predictable pattern: onset week 1-3, peak week 3-5, gradual improvement week 6-10, resolution by week 12 at stable dose. If fatigue persists beyond 12 weeks, nutritional adjustments or medical evaluation is needed.

Can I take Rybelsus at night to avoid tiredness? Rybelsus must be taken on an empty stomach first thing in the morning, at least 30 minutes before food or other medications. The timing is required for absorption, not side effect management. Taking it at night would not work and would reduce effectiveness.

Should I stop Rybelsus if I feel tired? Not without provider guidance. Most fatigue is manageable with hydration, adequate caloric intake (1,200-1,400 calories minimum), and protein distribution across meals. If fatigue is severe and interfering with daily function, contact your provider to discuss dose adjustment.

Does Rybelsus fatigue mean it's working? Mild fatigue during the first 8 weeks often indicates adequate GLP-1 receptor engagement and meaningful caloric restriction. Patients with mild side effects lose slightly more weight than those with zero side effects. Severe fatigue, however, predicts poor adherence and should be addressed.

How much water should I drink on Rybelsus to prevent fatigue? Target 0.5 ounces per pound of body weight daily (a 150 lb person needs 75 oz). Drink 16-20 oz within an hour of waking and 8-12 oz before each meal. Add electrolytes if nausea is present. Dehydration-related fatigue improves within 24-48 hours of consistent hydration.

What should I eat on Rybelsus if I'm tired? Prioritize protein (80-100 grams per day distributed across meals), moderate complex carbohydrates (75-150 grams per day), and calorie-dense nutrient-rich foods like nuts, avocado, and olive oil. Maintain minimum 1,200-1,400 calories daily even if appetite is low.

Is fatigue on Rybelsus a sign of low blood sugar? Rybelsus rarely causes true hypoglycemia (blood glucose below 70 mg/dL) when used alone. However, patients with diabetes whose glucose normalizes rapidly may feel symptoms of relative hypoglycemia even at normal glucose levels (80-110 mg/dL). Check your glucose if concerned.

Can I drink coffee on Rybelsus for energy? Yes. Coffee does not interact with Rybelsus, but you must wait at least 30 minutes after taking Rybelsus before drinking coffee (same rule as food). Moderate caffeine (1-2 cups daily) can help manage fatigue, but excessive caffeine may worsen nausea.

Does Rybelsus cause fatigue more than Ozempic? Oral semaglutide (Rybelsus) has slightly higher fatigue rates (11.3%) compared to injectable semaglutide (6.9% in STEP 1 trial). The difference likely reflects higher GI side effect burden with oral formulation, which increases dehydration risk. The mechanisms are otherwise identical.

Will exercise help or worsen Rybelsus fatigue? Moderate exercise (walking 20-30 minutes daily) helps by improving insulin sensitivity and mood. High-intensity exercise during the adaptation window (weeks 1-8) often worsens fatigue because energy availability is already reduced. Adjust exercise intensity to match current energy levels.

Can I take vitamins or supplements for Rybelsus fatigue? B12, iron, and vitamin D deficiencies can worsen fatigue and are common in patients on GLP-1 medications due to reduced dietary intake. Check levels with your provider. Magnesium glycinate 200-400 mg at bedtime can improve sleep quality, which indirectly helps fatigue.

Does Rybelsus fatigue mean I'm not eating enough? Often, yes. If you are consuming fewer than 1,200 calories per day (women) or 1,500 calories per day (men), adaptive metabolic slowdown is likely causing or worsening fatigue. Track intake for 3 days. If below threshold, intentionally add 200-300 calories daily.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Aroda VR et al. Efficacy and Safety of Oral Semaglutide by Baseline HbA1c in the PIONEER 1 Trial. Diabetes Care. 2019.
3. Pratley RE et al. Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4). Lancet. 2019.
4. Pawlikowska T et al. Population Based Study of Fatigue and Psychological Distress. British Medical Journal. 1994.
5. Blonde L et al. Gastrointestinal Tolerability of Once-Weekly GLP-1 Receptor Agonists. Diabetes, Obesity and Metabolism. 2023.
6. Leibel RL et al. Changes in Energy Expenditure Resulting from Altered Body Weight. American Journal of Clinical Nutrition. 1995.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. Obesity. 2024.
8. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Care. 2020.
10. Smits MM et al. Effect of GLP-1 Receptor Agonists on Gastric Emptying. Diabetes Care. 2016.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. JAMA. 2021.
12. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin. JAMA. 2019.
13. Sorli C et al. Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo. Diabetes, Obesity and Metabolism. 2017.
14. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk. MyFitnessPal, Cronometer, and LoseIt are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.